Best Immunotherapy Companies in Texas, United States
The 59 best Immunotherapy companies in Texas, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Marker Therapeutics.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Texas
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Marker Therapeutics Developer of T-cell based therapeutics for cancer treatment 42Talent top 15%Funding top 18%News top 47%Tech top 50% All 9 signals ▾Talenttop 15% Fundingtop 18% Newstop 47% Techtop 50% Moattop 50% Marketbottom 43% Growthbottom 40% Globalbottom 32% Fin. healthbottom 29% Talent: Analyst team rating 5/5 Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $154M | 10 mo ago | 67 | — | DrupalApple iCloud MailMicrosoft 365+22 | — | — |
| 2 | AlloVir Developer of T-cell therapies to treat infectious diseases | $151M | 85 mo ago | 97 | David Hallal Co-Founder | — | 8 patents Ex vivo expansion of multivirus-specific T cells for transplant infection prophylaxis | — |
| 3 | Bellicum Developer of T cell therapies for the treatment of cancer and chronic infectious diseases | $138M | 142 mo ago | 108 | — | DrupalApple iCloud MailMicrosoft 365+20 | — | — |
| 4 | Gradalis Personalized cancer immunotherapy company advancing treatment through Vigil platform | $68M | 13 mo ago | 8 | — | — | 179 patents Nucleic‑acid therapeutics targeting cancer and genetic muscle disorders, including RNAi and neoantigen vaccines. | — |
| 5 | Allterum Developer of drugs for treating leukemia disease | $66M | 53 mo ago | 2 | — | — | — | — |
| 6 | Triumvira Immunologics Developer of T-cell therapies for treating cancers | $55M | 51 mo ago | 85 | Jonathan Bramson Co-Founder & Chairman | — | 48 patents Bispecific T‑cell engager antibodies targeting Claudin‑18.2, GUCY2C, and GPC3 for cancer immunotherapy. | — |
| 7 | Medicenna Therapeutics Developer of interleukin-4 Receptor (IL4R) targeted cytokines for cancer | $54M | 26 mo ago | 1 | — | DrupalPHPBootstrap+22 | — | — |
| 8 | ImmunoGenesis Developer of therapeutic solutions for treating tumors | $44M | 27 mo ago | 14 | Michael Curran Founder | WordPressMySQLPHP+18 | 18 patents Targeted hypoxia‑activated prodrugs and STING agonist combos for cancer immunotherapy | 1 partnership |
| 9 | DNAtrix Oncolytic virus platform for treating malignant glioma. | $43M | 46 mo ago | 13 | — | — | 81 patents Oncolytic adenovirus gene therapies targeting pediatric brain tumors and immune activation | — |
| 10 | Forbius Biotech innovator dedicated to advancing healthcare solutions for better health | $32M | 80 mo ago | 37 | — | — | — | — |
| 11 | CoRegen Developer of immunotherapeutics for the treatment of cancer | $27M | 14 mo ago | — | Steve Gorlin CEO | — | — | — |
| 12 | Vaxxinity Developer of vaccines for neurological disorders and infectious diseases | $27M | 63 mo ago | 92 | — | DrupalPHPZURB Foundation+21 | 34 patents Peptide immunotherapy targeting tau, amyloid‑beta and synuclein in neurodegenerative diseases | — |
| 13 | Pulmotect Developer of therapeutics against lung infections | $25M | 22 mo ago | 4 | — | — | 21 patents Immunomodulatory therapeutics targeting adaptive immunity for asthma and viral infection treatment | — |
| 14 | Aravive Biologics Developer of antibody inhibitors for camcer therapy | $24M | 115 mo ago | 5 | — | — | 39 patents AXL pathway inhibition via decoy receptors and peptides for anti‑metastatic cancer therapy | — |
| 15 | Invectys Developer of immunotherapeutic cancer treatments targeting HLA‑G antigen | $22M | 21 mo ago | 25 | Simon Wain-Hobson Co-Founder & CSO | WordPressMySQLPHP+19 | 4 patents Engineered CAR‑T cell immunotherapy targeting HLA‑G antigen | — |
| 16 | Coya Therapeutics Developer of therapeutics for cell therapy and exosome therapy | $20M | 20 mo ago | 6 | — | WordPressMySQLPHP+14 | — | — |
| 17 | Stellanova Therapeutics Developer of cancer therapies for targeting cancer-associated fibroblasts | $16M | 61 mo ago | 5 | Rosa Hwang Co-Founder | — | — | — |
| 18 | Cellenkos Developer of T-cell therapeutics to treat autoimmune and inflammatory diseases | $15M | 56 mo ago | 14 | — | — | 21 patents Regulatory T‑cell based cell therapies for immune modulation and disease treatment | — |
| 19 | Orano Med Developing targeted cancer therapies using Lead-212 radioisotope for alphatherapy | $15M | 30 mo ago | — | Julien Dodet President and CEO | Progress SitefinitySalesforcePIXIjs+20 | — | — |
| 20 | 7 Hills Pharma Developing integrin agonists to improve immunotherapies for cancer and genetic diseases | $15M | 26 mo ago | 9 | Upendra Marathi President & CEO | Cart FunctionalitySquarespace CommerceSquarespace+13 | — | — |
| 21 | Asylia Therapeutics Developer of medicines for cancer, autoimmune, and infectious diseases | $14M | 15 mo ago | 4 | Richard Jones Co-Founder | — | — | — |
| 22 | Memgen Developer of immunotherapies to treat cancer | $12M | 19 mo ago | 9 | — | — | 72 patents Oncolytic virus and CD40/TLR‑based immunotherapy platforms for cancer and vaccines | — |
| 23 | Diakonos Provider of immunotherapeutics for cancer treatment | $11M | 13 mo ago | — | Mike Wicks CEO | WordPressMySQLPHP+18 | — | 1 partnership |
| 24 | ImmunoMet Therapeutics Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies | $10M | 5 mo ago | 9 | Dean Welsch CEO | — | — | — |
| 25 | CrossBridge Bio Developer of Antibody-Drug Conjugate therapeutics | $10M | 20 mo ago | — | Zhiqiang An Co-Founder | WordPressMySQLPHP+19 | — | — |
| 26 | ImmuneSensor Developer of small-molecule drugs to treat cancer | $10M | 43 mo ago | 11 11 → 9 (-18%) | — | — | — | — |
| 27 | Fresh Wind Biotechnologies Developer of cellular immunotherapeutic solutions for the treatment of cancer | $10M | 67 mo ago | — | Fuli Yu Founder and CEO | — | — | — |
| 28 | Stingray Therapeutics Developer of immunotherapeutics for treating cancer | $8M | 16 mo ago | 6 | Sunil Sharma Co-Founder | — | — | — |
| 29 | Dialectic Therapeutics Developer of therapeutic solutions for treating cancer | $7M | 65 mo ago | 6 | David Genecov Co-Founder & CEO & Managing Director & President | — | — | — |
| 30 | Opexa Therapeutics Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis. | $6M | 160 mo ago | 9 | — | — | — | — |
| 31 | GenrAb Developer of neuroprotective monoclonal antibodies for treating neurological disorders | $6M | 14 mo ago | — | Larry Tiffany CEO | — | — | — |
| 32 | United Allergy Services Allergy testing and immunotherapy solutions empowering healthcare providers and improving patient lives | $5M | 158 mo ago | 219 219 → 352 (+61%) | — | WordPressMySQLPHP+26 | — | — |
| 33 | Ayuvis Developing immunotherapies to prevent and treat life-threatening diseases | $2M | 15 mo ago | 10 | Suchismita Acharya Founder & CEO | — | — | — |
| 34 | Alaunos Therapeutics Developer of adoptive TCR-T cell therapies for solid tumors. | $850K | 12 mo ago | 34 | — | DrupalPHPAmazon Web Services+20 | — | — |
| 35 | Mirata BioPharma Developing immuno-oncology drugs based on targeted granzyme B immunotherapy | $500K | 98 mo ago | — | Keizo Koya CEO | — | — | — |
| 36 | Pelican Therapeutics Developing antibody to stimulate memory CD8+ cytotoxic T cells for the treatment of cancer. | $410K | 78 mo ago | 3 | — | — | — | — |
| 37 | Icell Kealex Therapeutics Developing T cell engager-armed oncolytic virus for the treatment of solid tumours. | $223K | 73 mo ago | — | Shautong Song CEO & Founder | — | — | — |
| 38 | Courier Therapeutics Developer of immunotherapies for treating cancer | $204K | 94 mo ago | 2 | Sarah Hein Co-Founder | — | — | — |
| 39 | Kiromic Developer of small molecules-based therapeutic solutions for the treatment of cancer | $135K | 94 mo ago | 31 | — | — | 32 patents Cancer immunotherapy and nanoparticle-based therapeutics for solid and hematologic malignancies | — |
Top 12 Immunotherapy companies in Texas
#1
Public · Houston, Texas · founded 1991 · 67 employees$153.9Mraised▾
Developer of T-cell based therapeutics for cancer treatment. The company's lead product candidates are used against triple-negative breast cancer and ovarian cancer. The company is also developing peptide vaccines for the treatment purpose.
- Aug 2025Grant (prize money)$1.3M
- Jun 2025Grant (prize money)$1.2M
- May 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
#2
Series B · Houston, Texas · founded 2015 · 9 employees$10.2Mraised▾
Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies. The company focuses on developing innovative treatments by leveraging the unique metabolic signatures of cancer and immune cells. Their lead molecule targets Oxidative Phosphorylation, aiming to decrease aberrant cell growth and proliferation in targeted cancer cells and fibrosis. They are developing a library of biguanides with the potential for development as novel treatments for cancer and/or diseases of fibrosis. The company is dedicated to advancing science and improving patient outcomes through targeted therapeutic interventions in oncology and fibrosis. They are a clinical stage company.
- Jan 2026Series B$842.2K
- Mar 2017Series B$5M
- Mar 2016Series A$5.2M
#3
Series C · Carrollton, Texas · founded 2010 · 8 employees$67.9Mraised▾
Personalized cancer immunotherapy company advancing treatment through Vigil platform. This biotechnology company focuses on developing personalized therapeutics to treat cancer. They are developing Vigil, a proprietary immunotherapy platform for multiple advanced cancer indications. Vigil empowers a patient’s own immune system to identify and destroy cancer cells. Vigil's patient-specific approach has demonstrated success in research and clinical trial phases in treating ovarian cancer, with potential applications across other solid tumor types. Vigil can be used alone or in concert with other treatments. They are advancing cancer treatment through personalized immunotherapy. The company is focused on scientific research, medical research, and technology to make a difference in cancer treatment.
- Jun 2025Series C$12.7M
- Nov 2023Grant (prize money)$9.9M
- Mar 2018Series C$43.9M
- Jan 2013Series B$24M
#4
Series C · Houston, Texas · founded 2019$27.4Mraised▾
Developer of immunotherapeutics for the treatment of cancer. It offers a pipeline of drug candidates based on T regulatory cells and a small molecule inhibitor that blocks the transcriptional activity in cancer cells. It provides drugs for breast, lung, prostate, colorectal, and pancreatic cancer treatment.
- Apr 2025Series C$62.6M
- Jan 2025Series B$20.8M
- Feb 2024Series B$14.5M
- Aug 2022Series B$12.9M
#5
Seed · Houston, Texas · founded 2022$11.4Mraised▾
Provider of immunotherapeutics for cancer treatment. It offers Dendritic Cell Vaccines for Glioblastoma, Pancreatic cancer, Sarcoma, Intratumoral Injection for Bone Cancer, Head and Neck Cancer, and CAR T cell therapies for HER 2+ Breast Cancer, and solid tumors.
- Jun 2025Seed$20M
- Aug 2024Seed$11.4M
#6
Series A · Houston, Texas · founded 2019 · 4 employees$14.5Mraised▾
Developer of medicines for cancer, autoimmune, and infectious diseases. The company's lead antibody, ASY-77A, enhances antigen presentation by targeting the extracellular form of heat shock protein. Another candidate ASY-77A has produced complete regression of various cancer types including solid tumors such as breast and colon cancer, and blood-related cancers like multiple myeloma.
- Apr 2025Grant (prize money)$241.4K
- Apr 2022Grant (prize money)$246.5K
- Mar 2021Series A$14.5M
#7
Series A · Houston, Texas · founded 2010 · 25 employees$22.5Mraised▾
Developer of immunotherapeutic cancer treatments targeting HLA‑G antigen. The company specializes in developing CAR‑T cell therapies and monoclonal antibody treatments that target the HLA‑G immune checkpoint antigen commonly expressed by solid tumors. It operates clinical‑stage programs focused on anti‑HLA‑G and telomerase‑based platforms for restoring anti‑tumor immune function. The lead candidate is an anti‑HLA‑G CAR‑T therapy currently in early clinical trials in solid tumors. The company collaborates with academic and manufacturing institutions to scale process development and manufacturing workflows for clinical use.
- Sep 2024Series A$4M
- Mar 2023Grant (prize money)$301.5K
- Oct 2018Series A$17.1M
- Jul 2017Series A$4.9M
#8
Public · Houston, Texas · founded 2020 · 6 employees$20.4Mraised▾
Developer of therapeutics for cell therapy and exosome therapy. The company developed various products such as ALS 001 and EXO 001 for Amyotrophic Lateral Sclerosis, FTD 080 and EXO O50 for Frontotemporal Dementia, and AID 912 for Scleroderma.
- Oct 2024Post IPO$10M
- May 2024Post IPO$5M
- Dec 2023Post IPO$26.5M
- May 2022Series A$10.4M
#9
Series B · Houston, Texas · founded 2007 · 4 employees$25.1Mraised▾
Developer of therapeutics against lung infections. The lead candidate PUL-042 is an inhalant that stimulates the innate immune system in the lungs, protecting against a wide range of inhaled pathogens. It claims that the candidate has shown to protect against bacterial, fungal, and viral pathogens.
- Aug 2024Series B$10.3M
- Jun 2023Conventional Debt$300K
- Feb 2023Series A$3.5M
- Mar 2021Series A$3.5M
#10
Series A · Houston, Texas · founded 2018 · 6 employees$8.1Mraised▾
Stingray Therapeutics is developing immune-oncology therapies for treating cancer. The oral medicines developed are used to stimulate the innate immune system and block adaptive immune-suppressive proteins. The checkpoint inhibitors are used to inhibit the ENPP1 to prevent blocking of innate immunity (T-cells and antibodies) from killing the cancer cells.
- Feb 2025Grant (prize money)$3.5M
- Jan 2023Series A$6.6M
- Sep 2022Grant (prize money)$2M
- May 2021Seed$1.5M
#11
Series A · Houston, Texas · founded 2004 · 9 employees$12Mraised▾
Developer of immunotherapies to treat cancer. The company's lead immunotherapy, MEM-288, is to treat patients with advanced cancers including lung, breast, pancreatic, and prostate cancers. Other candidates include MEM 40 to treat COVID-19.
- Nov 2024Series A$950K
- Jun 2023Series A$625K
- Dec 2021Series A$9.8M
- Jul 2020Seed$575K
#12
Seed · Dallas, Texas · founded 2022$5.6Mraised▾
Developer of neuroprotective monoclonal antibodies for treating neurological disorders. It focuses on developing therapies that protect and treat patients with neurological diseases. The company's proprietary Antibody Gene Signature (AGS) technology identifies potentially therapeutic fully-human mAbs to treat neurological disorders. These antibodies leverage naturally created neuroprotective mechanisms found in individuals experiencing neurodegeneration. The company aims to prevent disease progression and provide neuroprotection.
- Apr 2025Seed$5.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology in Texas is moving
A read on the academic research around Immunology in Texas — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 961 papers.
MD Anderson and UT Southwestern lead Texas immunology research, dominated by CAR-T therapy and cancer immunotherapy biomarkers, with a cautiously optimistic tone reflecting advancement-heavy but concern-aware output.
- The University of Texas MD Anderson Cancer Center559
- The University of Texas Southwestern Medical Center158
- The University of Texas Health Science Center at Houston60
- The University of Texas Health Science Center at San Antonio42
- Texas Tech University33
- Immune system5→69
- Immunotherapy6→68
- Tumor microenvironment3→29
- Cancer2→27
- Cancer research4→28
- Immunotherapy15→164
- Immune system14→153
- Oncology2→71
- Cancer4→71
- Internal medicine6→56
- Immunotherapy4→56
- Immune system6→39
- Cancer1→20
- Internal medicine2→19
- Oncology1→16
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.